Bank of America Files Schedule 13G/A for Inhibrx Biosciences
A Schedule 13G/A concerning Inhibrx Biosciences was filed by Bank of America Corp.
Related stories
CEPCO Seeks Approval for Buyback of Up to 10% of Shares
CEPCO will seek shareholder approval for the buyback.
M impact | EQUITY | Oct 30, 2026, 02:05 AM UTC
Vale Q3 Profit Tumbles as Iron Ore Output Misses Forecasts
Vale’s adjusted EBITDA was in line.
M impact | EQUITY | Oct 30, 2026, 02:04 AM UTC
Taiwan's Taiex Falls 3.0% to 44983.64
M impact | EQUITY | Oct 30, 2026, 02:03 AM UTC
SAIC Motor Shares Fall 5.9% as Q3 Profit Plunges
SAIC Motor shares fell 5.9% in early trading to a two-month low. The automaker reported third-quarter net profit on Thursday.
M impact | EQUITY | Oct 30, 2026, 02:03 AM UTC
Boston Scientific Reports Q3 Sales of $5.138 Billion, Lowers 2026 EPS Guidance
Boston Scientific reported Q3 2026 sales of $5.138 billion, up 1.5% year over year, and adjusted EPS of $0.73. It lowered full-year adjusted EPS guidance to $3.16–$3.18, citing Chi
M impact | EQUITY | Oct 30, 2026, 02:02 AM UTC
Indonesia's Benchmark Stock Index Falls 0.9% to 5,054.729
M impact | EQUITY | Oct 30, 2026, 02:01 AM UTC